Unknown

Dataset Information

0

Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.


ABSTRACT: Context:Dipeptidyl peptidase 4 (DPP4) inhibitors may increase the risk of heart failure. Decreased degradation of vasoactive peptides like substance P [also degraded by angiotensin-converting enzyme (ACE)] and Y1 agonists peptide YY (PYY 1-36) and neuropeptide Y (NPY 1-36) could contribute. Objective:This study tested the hypothesis that there is an interactive effect of DPP4 inhibition and ACE inhibition (vs antihypertensive control subjects) on vasoactive peptides after a mixed meal. Participants and Design:Fifty-three patients with type 2 diabetes and hypertension were randomized to double-blind treatment with ramipril, valsartan, or amlodipine for 15 weeks in parallel groups. During the 5th, 10th, and 15th weeks, participants also received placebo + placebo, sitagliptin 100 mg/d + placebo, and sitagliptin + aprepitant 80 mg/d in random order. On the last day of each crossover treatment, participants underwent a mixed-meal study. Results:Sitagliptin increased postprandial glucagon-like peptide-1 and decreased glucose in all antihypertensive groups. Sitagliptin increased NPY 1-36 and decreased Y2 agonists NPY 3-36 and PYY 3-36 in all groups. During ramipril or valsartan, but not amlodipine, sitagliptin increased postprandial norepinephrine; substance P receptor blockade with aprepitant prevented this effect. Despite increased norepinephrine, sitagliptin decreased postprandial blood pressure during ACE inhibition. Conclusion:DPP4 inhibition increases postprandial concentrations of the Y1 agonist NPY 1-36. During treatment with an ACE inhibitor or angiotensin receptor blocker, DPP4 inhibition increased postprandial norepinephrine through a substance P receptor-dependent mechanism. Increased NPY 1-36 and norepinephrine could increase risk of heart failure but did not result in higher postprandial blood pressure.

SUBMITTER: Wilson JR 

PROVIDER: S-EPMC6734191 | biostudies-other | 2019 Oct

REPOSITORIES: biostudies-other

altmetric image

Publications

Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.

Wilson Jessica R JR   Kerman Scott Jafarian SJ   Hubers Scott A SA   Yu Chang C   Nian Hui H   Grouzmann Eric E   Eugster Philippe J PJ   Mayfield Dustin S DS   Brown Nancy J NJ  

Journal of the Endocrine Society 20190701 10


<h4>Context</h4>Dipeptidyl peptidase 4 (DPP4) inhibitors may increase the risk of heart failure. Decreased degradation of vasoactive peptides like substance P [also degraded by angiotensin-converting enzyme (ACE)] and Y1 agonists peptide YY (PYY 1-36) and neuropeptide Y (NPY 1-36) could contribute.<h4>Objective</h4>This study tested the hypothesis that there is an interactive effect of DPP4 inhibition and ACE inhibition (vs antihypertensive control subjects) on vasoactive peptides after a mixed  ...[more]

Similar Datasets

| S-EPMC3984385 | biostudies-literature
| S-EPMC6821704 | biostudies-literature
| S-EPMC6387447 | biostudies-literature
| S-EPMC4525143 | biostudies-literature
2011-12-31 | E-MTAB-583 | biostudies-arrayexpress
| S-EPMC7203631 | biostudies-literature
| S-EPMC4224594 | biostudies-literature
| S-EPMC7677484 | biostudies-literature
| S-EPMC4933943 | biostudies-literature
| S-EPMC6202157 | biostudies-literature